Response to Comment on: “Targeted anti-cancer agents and risk of venous thromboembolism”
Not available.
Saved in:
| Main Authors: | Melina Verso, Florian Moik, Mara Graziani, Alexander T. Cohen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-04-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/12028 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on: Targeted anti-cancer agents and risk of venous thromboembolism
by: Catherine Duane, et al.
Published: (2025-03-01) -
Validation of risk assessment models for venous thromboembolism in patients with cancer receiving systemic therapies
by: Nikola Vladić, et al.
Published: (2025-07-01) -
Comment on: Multimorbidity, comorbidity, frailty, and venous thromboembolism
by: Maria I. Zervou, et al.
Published: (2025-02-01) -
Arterial and venous thromboembolic events in patients with cancer treated with targeted therapies: a population-based cohort studyResearch in context
by: Florian Moik, et al.
Published: (2025-09-01) -
Risk of venous thromboembolism in patients with pancreatic cancer
by: O. I. Kit, et al.
Published: (2022-06-01)